EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has become the standard, first-line treatment for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.